<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307917</url>
  </required_header>
  <id_info>
    <org_study_id>A09-3502</org_study_id>
    <nct_id>NCT01307917</nct_id>
  </id_info>
  <brief_title>Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes</brief_title>
  <acronym>flavonoid</acronym>
  <official_title>Endothelial Dysfunction and the Role of Flavonoids in the Prevention of Nephropathy Among Pediatric Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is the most common metabolic disease of childhood. Vascular disease is a leading&#xD;
      complication of diabetes, and attempts to maintain close glycemic control do not prevent the&#xD;
      sequelae that claim the lives and quality of life of millions of diabetics each year. Up to&#xD;
      forty percent of patients with diabetes mellitus ultimately develop diabetic nephropathy, the&#xD;
      most common cause of end-stage renal disease requiring dialysis in the US. Flavonoid-rich&#xD;
      diets are a promising intervention to prevent the endothelial dysfunction that apparently&#xD;
      leads to this deadly complication. The mechanisms are still unclear but probably involve&#xD;
      nitric oxide synthesis. The investigators hypothesize that early maintenance of the integrity&#xD;
      of renal vasculature will significantly improve the lifelong prognosis for patients with&#xD;
      diabetes. Flavonoids with anti-inflammatory and antioxidant activities could be used to&#xD;
      protect endothelial function, and together with good glycemic control, prevent the&#xD;
      development and progression of nephropathy. The investigators aims are to:&#xD;
&#xD;
        1. compare endothelial function by studying reactive hyperemia, nitric oxide, and&#xD;
           proinflammatory factors in adolescents (12-21 years old) with diabetes versus healthy&#xD;
           sex- and age-matched control subjects.&#xD;
&#xD;
        2. identify early markers in urine for vascular endothelial injury.&#xD;
&#xD;
        3. examine the effects of flavonoids on vascular function, urine nitric oxide, and&#xD;
           proinflammatory factors in patients with diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our proposal is the first attempt to use flavonoids to treat endothelial dysfunction as a&#xD;
      causative factor of nephropathy in a pediatric population with diabetes. The investigators&#xD;
      plan to recruit 40 adolescents with type 1 or 2 diabetes mellitus and 40 healthy peers into a&#xD;
      double-blind, randomized, controlled study. Peripheral arterial tonometry, a noninvasive&#xD;
      method to assess vascular status, will be employed to study endothelial function in both&#xD;
      groups. Measurements of renal nitric oxide synthesis will be assayed using a nitric oxide&#xD;
      chemiluminescence analyzer. Urinary protein microarray analyses will be conducted to assess&#xD;
      early markers of kidney inflammation. The array is a multiplex sandwich fluorescent&#xD;
      immunoassay for the simultaneous quantification of interleukin-1b (IL-1b), IL-2, IL-4, IL-6,&#xD;
      IL-8, IL-10, IL-12, interferon gamma, tumor necrosis factor-alpha, macrophage inflammatory&#xD;
      protein-1-alpha and beta, and RANTES. The initial acute response and effect of 14 days of&#xD;
      treatment with a flavonoid-rich capsulated supplement will be compared to a placebo. Study&#xD;
      subjects will return for baseline assessments a week after the final flavonoid supplement to&#xD;
      evaluate the sustainability of the response. Differences between group means for the measured&#xD;
      variables before, during, and after the interventions will be tested for statistical&#xD;
      significance using paired t-tests and nonparametric statistics. Univariate correlations will&#xD;
      be calculated using Pearson's r.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No funding ever received&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare endothelial function by studying reactive hyperemia, nitric oxide, and proinflammatory factors in adolescents (12-21 years old) with diabetes vs. healthy sex- and age-matched control subjects.</measure>
    <time_frame>day 0; day 14; day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>identify early markers in urine for vascular endothelial injury</measure>
    <time_frame>screening, day 0, day 14, day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>examine the effects of flavonoids on vascular function, urine nitric oxide, and proinflammatory factors in patients with diabetes mellitus</measure>
    <time_frame>day 0, day 14, day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>healthy controls high flavonoid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 healthy adolescents (12-21 years old) receiving the flavonoid-rich capsule/supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls low flavonoid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 healthy adolescents (12-21 years old) receiving the placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1DM or T2DM high flavonoid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the capsule/supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1DM or T2DM low flavonoid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>flavonoids</intervention_name>
    <description>for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.</description>
    <arm_group_label>T1DM or T2DM high flavonoid</arm_group_label>
    <arm_group_label>T1DM or T2DM low flavonoid</arm_group_label>
    <arm_group_label>healthy controls high flavonoid</arm_group_label>
    <arm_group_label>healthy controls low flavonoid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adolescents 12 - 21 years old&#xD;
&#xD;
          -  with T1DM or T2DM and their healthy age- and sex-matched peers&#xD;
&#xD;
          -  DM subjects must maintain good glycemic control with HbA1C &lt; 11&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no co-morbidities that could lead to inflammation or decline in renal function will be&#xD;
             allowed&#xD;
&#xD;
          -  no non-steroidal anti-inflammatory drugs should be taken, for any reason, within 48&#xD;
             hours prior to the study days&#xD;
&#xD;
          -  no smoking will be permitted on the day of Pre-Study Evaluation or Study Days 0, 14,&#xD;
             or 21&#xD;
&#xD;
          -  controls should not be taking any medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Vasylyeva, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center School of Medicine</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2011</study_first_posted>
  <last_update_submitted>December 14, 2012</last_update_submitted>
  <last_update_submitted_qc>December 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>diabetic nephropathy</keyword>
  <keyword>vascular endothelial dysfunction</keyword>
  <keyword>flavonoids</keyword>
  <keyword>flow-mediated dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

